27 days
Submission to first decision
16 days
Acceptance to publication

BioDrugs covers the development and therapeutic application of biotechnology-based pharmaceuticals and diagnostic products for the treatment of human disease. The Journal includes:
Definitive reviews on topics relating to the development and use of biotechnology in healthcare and the management of disease.
Systematic reviews that collate empirical evidence to answer a specific research question, using explicit, systematic methods as outlined by the PRISMA statement.
Original research articles on the clinical development and therapeutic application of biotechnology-based pharmaceuticals and diagnostic products.
Leading/Current Opinion articles providing an overview of contentious or emerging issues and key regulatory and ethical issues.
Adis Drug Evaluations reviewing the properties and place in therapy of biotechnology-based drugs.
Adis Biosimilar Briefs summarizing key characteristics and clinical use of biosimilar drugs.
Additional enhanced features (including slide sets, videos and animations) can be published with articles; these are designed to increase the visibility, readership and educational value of the journal’s content. In addition, articles published in BioDrugs may be accompanied by plain language summaries to assist readers in understanding important medical advances.
All manuscripts are subject to peer review by international experts. Letters to the Editor are welcomed and will be considered for publication.

Leading Article
Review Article
Current Opinion
Systematic Review
Original Research
Letter to the Editor
Editorial/Commentary

Editor (Adis International Limited, Auckland, New Zealand):
Kathy Fraser
Section Editors (Adis International Limited, Auckland, New Zealand):
Martin Chopra
Rod McNab
David Williamson
Editorial Board:
L. Bergmann, Klinikum der Johann Wolfgang Goethe-Universitat, Frankfurt, Germany
G.D. Demetri, Dana Farber Cancer Institute, Boston, MA, USA
T.R. Flotte, University of Massachusetts Medical School, Worcester, MA, USA
T.M. Ganey, Vivex Biomedical, Atlanta, GA, USA
A. Ganser, Hannover Medical School, Hannover, Germany
H-P. Gerber, 3T Biosciences, Palo Alto, CA, USA
T.J. Giezen, Foundation Pharmacy for Hospitals in Haarlem, Haarlem, the Netherlands
B. Groner, Georg-Speyer-Haus, Institute for Biomedical Research, Frankfurt, Germany
F. Guilhot, Université de Poitiers, Poitiers, France
W.H. Hildebrand, University of Oklahoma, Oklahoma City, OK, USA
P. Moingeon, Stallergenes, Paris, France
D. Müller, Universitat Stuttgart, Stuttgart, Germany
W. Park, Inha University Medical School, Incheon, Republic of Korea
C. Picado, Hospital Clinic de Barcelona, Barcelona, Spain
T. Schirrmann, YUMAB GmbH, Braunschweig, Germany
S. Sharfstein, SUNY Polytechnic Institute, Albany, NY, USA
C.A. Stein, City of Hope Medical Center, Duarte, CA, USA
R.C. Stevens, University of Southern California, Los Angeles, CA, USA
W.R. Strohl, BiStro Biotech Consulting, Bridgewater, NJ, USA
B.A. Sullenger, Duke University Medical Center, Durham, NC, USA
J. Terrett, Crispr Therapeutics, Inc., Cambridge, MA, USA
G. Trifirò, University of Messina, Sicily, Italy
P. Trzonkowski, Medical University of Gdansk, Gdansk, Poland
J.W. Van der Meer, University Medical Center St Radboud, Nijmegen, the Netherlands
G. Woollett, Avalere Health, Washington, DC, USA